CTIS.eu › Cities › Spain › Barcelona
Barcelona
Spain
3,391 total trials
1,343 recruiting
Filter these 3,391 trials by phase, condition, sponsor and more.
Open in Search →
2023-505980-36-00
5
2019-09-19
Primary progressive multiple sclerosis (PPMS)
2024-511542-39-00
10
2019-09-16
Newly diagnosed primary glioblastoma multiforme (ndGBM)
2023-505321-14-00
10
2019-09-06
Warm Autoimmune Hemolytic Anemia
2023-510427-29-00
4
2019-09-04
Thymidine kinase 2 deficiency
2024-516847-23-00
4
2019-08-27
ER-positive and HER2-negative metastatic or locally advanced breast ca
2024-512260-54-00
5
2019-08-20
Primary Hyperoxaluria
2022-502616-37-00
9
2019-07-30
Relapsed/Refractory B-Cell Non-Hodgkin’s Lymphoma (r/r B-cell NHL)
2023-504930-23-00
5
2019-07-19
Episodic Migraine
2023-506153-38-00
5
2019-07-11
High-risk localized or locally advanced prostate cancer
2023-509605-77-00
1
2019-06-27
Advanced solid tumours
2024-514274-46-00
5
2019-06-21
Solid Tumors
2023-505223-31-00
4
2019-06-14
Localized ER+ breast cancer
2024-516478-31-00
5
2019-06-12
progressed thyroid cancer
2023-508264-29-00
5
2019-06-11
Advanced Renal Cell Carcinoma with Intermediate- or Poor-Risk Factors
2023-510268-11-00
4
2019-06-11
Cervical cancer
2023-504932-16-00
5
2019-06-04
Muscle Invasive Bladder Cancer
2023-508681-15-00
4
2019-05-28
Adult focal (partial onset) epilepsy
2023-510357-42-00
5
2019-05-22
hormone receptor (HR)-positive, HER2-negative,
early breast cancer (EB
2024-511953-23-00
5
2019-05-17
Hematopoietic Stem Cell mobilization autologous transplantation in Mul
2023-509305-68-00
5
2019-05-16
Pulmonary arterial hypertension (PAH)
2023-506827-26-00
5
2019-05-02
While it is well-established that long-term good glycaemic control wil
2023-509059-15-00
7
2019-04-30
Malignant solid tumors: endometrial carcinoma (EC), urothelial carcino
2024-512667-31-00
5
2019-04-23
Main cohort: Patients with unresected Stage I/II, lymph-node negative
2023-509087-20-00
5
2019-04-16
Metastatic Castration-resistant Prostate Cancer
Showing 2,401–2,424 of 3,391 trials